Deals In Depth: September 2016
Executive Summary
Teva is the latest pharma taking a bet on the risky anti-nerve growth factor field in a $3 billion deal with Regeneron; Abbott divested its medical optics business to J&J for $4 billion. Device financing increased significantly, thanks to a $2 billion debt offering by Acelity/Kinetic Concepts.